ALAMEDA, Calif. -- InSite Vision Incorporated (AMEX:ISV), an ophthalmic therapeutics, diagnostics and drug delivery company, announced today that the company will release 2007 first quarter results on Wednesday, May 9, 2007.
Kumar Chandrasekaran, PhD, chief executive officer, will host a financial community conference call beginning at 4:30 p.m. EDT on Wednesday, May 9, 2007 to discuss these results.
Individuals interested in listening to the conference call may do so by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will have to enter the account number 286 and conference ID 240928.
The live conference call will also be webcast and available on the Internet at www.InvestorCalendar.com as well as the Company's website at www.insitevision.com. A recording of the call will be available for 90 days following its completion of the conference call. In addition, the Company's first quarter earnings release will be posted to the Company's web site and furnished to the Securities and Exchange Commission on a Form 8-K prior to the conference call described above.
About InSite Vision Incorporated
InSite Vision is an ophthalmic company primarily focused on developing therapies that treat ocular infections, glaucoma and retinal diseases. InSite Vision's lead product is AzaSite[TM], a topical anti-infective which targets infections of the eye, which was approved by the FDA in April 2007. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen which is attractive to both the eye-care patient and physician.
InSite Vision currently expects AzaSite to be commercially launched in the United States in the second half of 2007. Inspire Pharmaceuticals (NASDAQ:ISPH) has the responsibility to commercialize AzaSite in the U.S. and Canada in accordance with the parties' out-license agreement. InSite plans to pursue additional commercial partnerships during 2007 to address AzaSite market opportunities outside the U.S. and Canada.
The Company will continue to build on its azithromycin/DuraSite technology platform by developing AzaSite Plus as its follow-on to AzaSite. AzaSite Plus is an antibiotic and corticosteroid combination product, where the antibiotic inhibits ocular bacterial proliferation while the corticoseroid allows suppression of the inflammatory response.
Additional information can be found at our website, www.insitevision.com.
This news release contains, among other things, certain statements of a forward-looking nature relating to future events, such the anticipated commercialization of AzaSite and other product candidates, the Company's plans to seek corporate collaborations to expand AzaSite outside the U.S. and Canada and build on its AzaSite technology platform, the timing of the Company's first quarter 2007 earnings release and related conference call, and the Company's plan to post its first quarter 2007 results on its web site and furnish such information to the SEC on a Current Report on Form 8-K prior to such call. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain substantial additional funding to continue its operations; the results of InSite Vision's clinical trials for AzaSite Plus and other product candidates; the ability to commercialize AzaSite and the timing thereof; the ability to obtain FDA approval for additional product candidates in the future; the ability of InSite Vision to enter into a corporate collaboration for AzaSite outside the U.S. and Canada and with respect to its other product candidates; InSite Vision's ability to expand its technology platform to include additional indications; the effects of its expense control activities on its operations and product development; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and AzaSite Plus; its reliance on third parties, including Inspire, for the development, marketing and sale of its products; the success of the Company's relationship with Inspirethe initiation and results of preclinical and clinical studies; and its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others. Reference is made to the discussion of these and other risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly reports on Form 10-Q, under the caption "Risk Factors" and elsewhere in such reports. Any forward looking statements or projections are based on the limited information currently available to InSite Vision, which is subject to change. Although any such forward looking statements or projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release is still valid at any later date.
Note to Editors: OcuGene(R) is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite(R) and OcuGene(R) are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.
No comments:
Post a Comment